Acute myeloid leukemia

Bone marrow is the factory inside your bones that makes blood. Every red cell that carries oxygen, every white cell that fights infection and every platelet that stops a cut bleeding starts there, as an immature cell that grows up into the thing your body needs.

A blast is one of those immature cells — an apprentice, on its way to becoming something useful. In acute myeloid leukemia the apprentice stops developing, keeps dividing, and stops dying on schedule. The marrow fills with cells that will never do a job.

“Acute” means it moves fast, over weeks rather than years. “Myeloid” names which of the two roads out of the marrow the cell was on — the road toward red cells, platelets and most white cells, rather than the lymphoid road. Cross those two questions, fast or slow and myeloid or lymphoid, and you get the four main leukemias: AML, ALL, CML and CLL. They are genuinely different diseases with different treatments.

In most people, no cause is ever found. AML is not contagious, it is only rarely inherited, and it is not something a person brings on themselves by anything they did or failed to do.

What has happened is a change in the DNA of a single blood-forming cell — an error in the instructions that tell it when to grow up and when to stop dividing. That cell then copies its mistake into everything it produces. Known risk factors exist, including previous chemotherapy or radiotherapy, some inherited conditions and some chemical exposures, but most people diagnosed have none of them.

Genetic testing of the leukemia cells is now part of diagnosis, and it does more than name the disease. It sorts the leukemia into favorable, intermediate or adverse risk, and that sorting is one of the main inputs into whether anyone starts looking for a donor.

Leukemia cells fill the marrow and crowd out the healthy cells developing there. The damage shows up as the absence of the three things the marrow should be making.

Too few red cells means tiredness that sleep does not fix, breathlessness on stairs, and pallor. Too few platelets means bruises that arrive without a knock, nosebleeds, and cuts that keep oozing. Too few working white cells means infections that arrive often, last too long, and come back.

None of it announces itself as cancer. Every one of those signs has ordinary explanations, and the overwhelming majority of people who have them do not have leukemia. But the disguise is also why AML is so often found late.

Treatment usually starts with chemotherapy, and what chemotherapy does is kill cells that divide quickly. Leukemia cells divide quickly, so they are hit hardest — but so is the lining of the mouth and gut, the hair follicles, and the marrow itself. That is where most of the side effects come from.

For many people chemotherapy brings the marrow back within normal limits and clears blasts from the blood. That is remission. Remission is not the same as cure, and the distinction matters: it is the point at which a team may begin looking for a donor, because the question has become whether the leukemia will return.

Not everyone is treated the same way. Intensive chemotherapy suits some people; lower-intensity treatment built around venetoclax suits others, and age and general health weigh heavily in that choice. Some AML is driven by a specific mutation — FLT3 or IDH, for example — and there are drugs aimed at those directly. Acute promyelocytic leukemia, a subtype of AML, is treated so differently that it is a separate condition in this library.

A transplant is offered when the risk of the leukemia returning outweighs the risk of the transplant itself. That is a judgment about one person, made by that person and their treating team, and it is not one this page can make.

If a transplant goes ahead, it starts with about one to two weeks of conditioning. St. Jude, explaining it to the families of children, puts its three jobs plainly: make room for the donor cells to grow, weaken the immune system so the body accepts them, and kill any cancer cells left behind. This is the genuinely dangerous stretch — for a period of days the patient has almost no working marrow at all, deliberately.

The transplant itself is not surgery. The cells run in through a line that is already in place, over anything from half an hour to a few hours, and it looks like a blood transfusion. Many recipients count a second birthday from that day for the rest of their lives.

Then comes waiting. Blood is drawn every morning. Until the donated cells take hold, the patient has almost no immune defenses and lives on red cells and platelets transfused from other donors entirely. Engraftment is the first morning the count rises instead of falling. Families learn to read a blood panel the way other people read a weather forecast.

The first hundred days are watched most closely. After that comes a slower rebuild: months of immunosuppression, an immune system that takes something like one to two years to come back, and childhood vaccinations given again from scratch, because the old immunity left with the old marrow.

AML is one of the conditions where a stranger genuinely can be the match. When a transplant is the right route and no one in the family is compatible, the donor comes from a registry — someone who once filled in a form and rubbed a swab inside their cheek.

What that person gives is not spare parts. It is a living immune system. The donor’s cells rebuild the blood, and they can also recognize leukemia cells that survived treatment and attack them. That effect is called graft-versus-leukemia, and it is a major reason a donor transplant can work where chemotherapy alone has not. It is also why the match has to be so close: those same cells have to recognize the body they land in.